目次
Table of Content
1. Research Methodology
2. Introduction To MCL1 Inhibitors
2.1 MCL1 as Therapeutic Target
2.2 Role of MCL1 in Cancer
3. MCL1 Inhibitors - Mechanism of Action
3.1 Indirect Inhibition of MCL1
3.2 Direct Inhibition of MCL1
4. MCL1 Inhibitor Drug Clinical Innovation by Indication
4.1 Leukemia
4.2 Lymphoma
4.3 Multiple Myeloma
4.4 Solid Cancers
4.4.1 Breast cancer
4.4.2 Lung Cancer
4.4.3 Melanoma
4.4.4 Colorectal cancer
5. Global MCL1 Inhibitor Drug Market Opportunity Outlook
5.1 Current Clinical Research Landscape
5.2 MCL1 Inhibitor Drug Future Commercialization Opportunities
6. Global MCL1 Inhibitor Drugs Clinical Trials Overview
6.1 By Company
6.2 By Country
6.3 By Indication
6.4 By Patient Segment
6.5 By Phase
7. Global MCL1 Inhibitor Drugs Clinical Trials Insight By Company, Indication and Phase
7.1 Preclinical
7.2 Phase-I
7.3 Phase-I/II
7.4 Phase-II
8. Marketed MCL1 Inhibitor Drug Clinical Insight
9. Competitive Landscape
9.1 Amgen
9.2 Ascentage Pharma
9.3 Broad Institute
9.4 Captor Therapeutics
9.5 Cyclacel Pharmaceuticals
9.6 Gilead Sciences
9.7 Prelude Therapeutics
9.8 Servier
9.9 Sirnaomics
9.10 Teva Pharmaceutical Industries
9.11 University Of Innsbruck
9.12 Vernalis
9.13 Vichem Chemie
List of Figures & Tables
Figure 4-1: S63845/MIK665 - Phase I Study and Phase I/II Study (NCT04702425 and
NCT04629443) Initiation and Completion Year
Figure 4-2: AMG 176 Phase I Study (NCT05209152) - Initiation and Completion Year
Figure 4-3: AMG 176 Phase I Study (NCT02675452) - Initiation and Completion Year
Figure 4-4: MIK665 - Study Initiation and Completion Year
Figure 4-5: PRT1419 - Study Initiation and Completion Year
Figure 4-6: AMG 176 Phase I Study (NCT02675452) - Initiation and Completion Year
Figure 4-7: MIK665 Phase I Study (NCT04702425) - Initiation and Completion Year
Figure 6-1: Global - MCL1 Inhibitor Drugs Trials by Company (Numbers), 2023
Figure 6-2: Global - MCL1 Inhibitor Drugs Trials by Country (Numbers), 2023
Figure 6-3: Global - MCL1 Inhibitor Drugs Trials by Indication (Numbers), 2023
Figure 6-4: Global - MCL1 Inhibitor Drugs Trials by Patient Segment (Numbers), 2023
Figure 6-5: Global - MCL1 Inhibitor Drugs Trials by Phase (Numbers), 2023
Table 4-1: Lymphoma - MCL1 Inhibitors Currently Under Clinical Trials
